Lisata Therapeutics, Inc.LSTANASDAQ
Loading
Year-over-year research & development expense growth
Latest
-42.06%
↓ 283% vs avg
Percentile
P8
Near historical low
Streak
1 qtr
Consecutive declineDecelerating
Average
22.97%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -42.06% |
| Q3 2025 | -13.05% |
| Q2 2025 | -13.41% |
| Q1 2025 | -11.80% |
| Q4 2024 | 16.05% |
| Q3 2024 | -2.27% |
| Q2 2024 | -19.75% |
| Q1 2024 | 7.57% |
| Q4 2023 | -10.86% |
| Q3 2023 | 6.89% |
| Q2 2023 | -0.53% |
| Q1 2023 | 0.32% |
| Q4 2022 | -90.60% |
| Q3 2022 | 942.92% |
| Q2 2022 | -1.49% |
| Q1 2022 | -20.89% |
| Q4 2021 | 0.61% |
| Q3 2021 | -4.71% |
| Q2 2021 | -14.72% |
| Q1 2021 | 74.61% |
| Q4 2020 | -4.03% |
| Q3 2020 | 66.61% |
| Q2 2020 | 21.28% |
| Q1 2020 | -45.83% |
| Q4 2019 | -7.89% |
| Q3 2019 | 0.54% |
| Q2 2019 | 46.61% |
| Q1 2019 | 35.15% |
| Q4 2018 | -34.46% |
| Q3 2018 | -15.50% |
| Q2 2018 | -4.86% |
| Q1 2018 | -45.51% |
| Q4 2017 | 46.42% |
| Q3 2017 | -16.15% |
| Q2 2017 | 14.81% |
| Q1 2017 | 44.76% |
| Q4 2016 | -13.01% |
| Q3 2016 | -34.08% |
| Q2 2016 | -23.60% |
| Q1 2016 | 84.84% |